View in EDS

A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2–11 Years with Moderate to Severe Atopic Dermatitis: Ruxolitinib Cream: Pediatric Maximum-Use Trial: L. S. Gold et al.

Saved in:
Bibliographic Details
Title: A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2–11 Years with Moderate to Severe Atopic Dermatitis: Ruxolitinib Cream: Pediatric Maximum-Use Trial: L. S. Gold et al.
Authors: Stein Gold, Linda1 LSTEIN1@hfhs.org, Bissonnette, Robert2, Forman, Seth3, Zaenglein, Andrea4, Kuo, YuTzu5, Angel, Brett5, Chen, Xuejun5, Kallender, Howard5, Paller, Amy S.6
Source: American Journal of Clinical Dermatology. Mar2025, Vol. 26 Issue 2, p275-289. 15p.
Database: Academic Search Ultimate
Description
ISSN:11750561
DOI:10.1007/s40257-024-00909-5